Overview

Prucalopride is a dihydrobenzofurancarboxamide derivative and a highly selective agonist of the serotonin 5-HT4 receptor, developed by Janssen Pharmaceutica and approved in Europe (2009), Canada (2011), and the United States (2018, marketed as Motegrity) for the treatment of chronic idiopathic constipation (CIC) in adults who have not achieved adequate relief with laxatives. Its development addressed a critical unmet need, as previous 5-HT4 agonists — notably cisapride and tegaserod — were withdrawn or restricted due to cardiovascular adverse effects (QT prolongation and cardiac ischemic events, respectively). Prucalopride's high selectivity for the 5-HT4 receptor (>150-fold selectivity over other serotonin receptor subtypes and the hERG potassium channel) confers a significantly improved cardiac safety profile.

The 5-HT4 receptor is expressed throughout the gastrointestinal tract, particularly in the myenteric plexus, where its activation initiates the peristaltic reflex by triggering acetylcholine release from excitatory motor neurons. Prucalopride stimulates this pathway, producing coordinated propulsive contractions that accelerate colonic transit. Unlike stimulant laxatives that primarily affect water secretion or direct smooth muscle contraction, prucalopride restores physiological motility patterns — enhancing high-amplitude propagating contractions, the primary propulsive force in the colon. Clinical trials have demonstrated that prucalopride (2 mg once daily) significantly increases the proportion of patients achieving three or more spontaneous complete bowel movements per week, improves stool consistency, reduces straining, and enhances patient satisfaction and quality of life.

Prucalopride is generally well tolerated, with headache, nausea, abdominal pain, and diarrhea as the most common adverse effects, typically occurring on the first day of treatment and resolving subsequently. Extensive cardiovascular safety studies, including thorough QT studies and long-term monitoring, have confirmed no clinically meaningful effects on cardiac repolarization or ischemic risk. Prucalopride represents a distinct mechanism from osmotic laxatives like polyethylene glycol, secretagogues like linaclotide and lubiprostone, and bulk-forming agents. Its prokinetic action complements the motility-supporting effects of ginger and artichoke extract, and it occupies a role similar to the gastroprokinetic effects of itopride but targeted to the lower gastrointestinal tract.

Mechanism of Action

Mechanism of Action: Prucalopride

Prucalopride is a dihydrobenzofurancarboxamide derivative that acts as a highly selective, high-affinity agonist at serotonin 5-HT4 receptors. Unlike older prokinetic agents, it has minimal affinity for other serotonin receptors or the hERG potassium channel, resulting in a favorable cardiac safety profile.

5-HT4 Receptor Pharmacology

Prucalopride binds 5-HT4 receptors with >150-fold selectivity over other serotonin receptor subtypes. Receptor activation couples to Gs proteins, stimulating adenylyl cyclase and increasing cAMP production. This enhances neuronal excitability in the enteric nervous system and facilitates neurotransmitter release at neuroeffector junctions.

Enteric Neural Circuit Activation

In the myenteric plexus, prucalopride activates both excitatory cholinergic motor neurons (releasing ACh and substance P) and inhibitory motor neurons (releasing NO and VIP). This dual activation enables coordinated peristaltic reflexes: contraction proximal to the bolus and relaxation distally, propelling intestinal contents aborally.

Colonic Motility Enhancement

Prucalopride significantly increases the frequency and amplitude of high-amplitude propagating contractions (HAPCs) in the colon, which are the primary motor pattern responsible for mass movement and defecation. It also enhances colonic transit by increasing the basal motor index and reducing colonic tone.

Neurotrophic Effects

Emerging evidence suggests 5-HT4 receptor activation has neurotrophic properties in the enteric nervous system, potentially promoting neuronal survival and network integrity. This may contribute to sustained efficacy with chronic use, as the enteric nervous system maintains improved function.

Pharmacokinetic Considerations

Prucalopride achieves >90% oral bioavailability with a half-life of approximately 24 hours, supporting once-daily dosing. It undergoes minimal CYP450 metabolism and is primarily excreted renally unchanged, resulting in few drug-drug interactions.

Reconstitution Calculator

Research

Safety Profile

Safety Profile: Prucalopride

Common Side Effects

• Headache (most frequent, reported in ~25% of patients), typically resolving within the first few days of treatment
• Gastrointestinal symptoms including nausea, abdominal pain, diarrhea, and flatulence
• Dizziness and fatigue, particularly during initial dosing
• Abdominal cramping and bloating

Serious Adverse Effects

• Suicidal ideation, depression, and psychiatric disturbances reported in post-marketing surveillance; causal relationship not fully established
• Severe diarrhea leading to dehydration and electrolyte imbalances, particularly in elderly patients
• Palpitations and tachycardia; rare cases of QT prolongation reported
• Ischemic colitis in rare post-marketing reports
• Severe allergic reactions including angioedema and anaphylaxis (very rare)

Contraindications

• Known hypersensitivity to prucalopride or any excipients
• Intestinal perforation or obstruction, obstructive ileus, or severe inflammatory conditions of the intestinal tract (Crohn's disease, ulcerative colitis, toxic megacolon)
• Dialysis-dependent renal impairment (CrCl < 30 mL/min requires dose reduction to 1 mg daily)
• Pregnancy and breastfeeding (insufficient safety data; animal studies showed no teratogenicity but caution advised)

Drug Interactions

• Erythromycin and ketoconazole: P-glycoprotein inhibitors may increase prucalopride plasma concentrations; clinical significance is limited but monitor
• Anticoagulants (warfarin): No clinically significant interaction demonstrated, but GI motility changes may theoretically alter absorption of co-administered drugs
• Anticholinergics: May counteract the prokinetic effects of prucalopride
• Other serotonergic agents: Theoretical risk of additive serotonergic effects; monitor for symptoms of serotonin syndrome

Population-Specific Considerations

• Elderly (≥65 years): Start with 1 mg daily; increased incidence of headache and GI side effects; monitor for dehydration
• Pediatric: Approved in some regions for children ≥6 months; dose based on weight; safety profile similar to adults
• Renal impairment: Reduce dose to 1 mg daily for severe impairment (CrCl < 30 mL/min)
• Hepatic impairment: No dose adjustment needed for mild-to-moderate; caution in severe hepatic impairment (limited data)
• Cardiac history: Use cautiously in patients with arrhythmias or conduction abnormalities

Pharmacokinetic Profile